Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35804999/
1 Department of Hematology, Gustave Roussy Cancer Campus, 94805 Villejuif, France. 2 Department of Hematology, Necker Hospital, Assistance Publique des Hopitaux de Paris (APHP), 75004 Paris, France. 3 Nantes Universite, Inserm, CNRS, Universite d'Angers, CRCI2NA, 44007 Nantes, France. 4 Department of Pathology, Cochin Hospital, Assistance Publique des Hopitaux de Paris (APHP), 75004 Paris, France.
Relevance: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) characterized by the translocation t(11;14) (q13;q32) and a poor response to rituximab-anthracycline-based chemotherapy. High-dose cytarabine-based regimens offer a durable response, but an important number of MCL patients are not eligible for intensive treatment and are ideal candidates for novel targeted therapies (such as BTK, proteasome or BCL2 inhibitors, Immunomodulatory Drugs (IMiDs), bispecific antibodies, or CAR-T cell therapy).